These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 21572125)

  • 1. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes.
    Lozano MD; Zulueta JJ; Echeveste JI; Gúrpide A; Seijo LM; Martín-Algarra S; Del Barrio A; Pio R; Idoate MA; Labiano T; Perez-Gracia JL
    Oncologist; 2011; 16(6):877-85. PubMed ID: 21572125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.
    Ulivi P; Romagnoli M; Chiadini E; Casoni GL; Capelli L; Gurioli C; Zoli W; Saragoni L; Dubini A; Tesei A; Amadori D; Poletti V
    Int J Oncol; 2012 Jul; 41(1):147-52. PubMed ID: 22504767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between EGFR and K-ras mutations and clinicopathological characteristics and response to erlotinib treatment in 301 Chinese patients with non-small cell lung cancer].
    Sun LN; Luan HL; Zang FL; Wang M; Dong N; Guo Y; Sun BC; Zhan ZL
    Zhonghua Zhong Liu Za Zhi; 2010 Sep; 32(9):667-70. PubMed ID: 21122380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
    Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
    Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of EGFR and K-ras mutations in non-small cell lung cancer using cytological specimens].
    Lu SS; Xu X; Guo HQ; Cao J; Pan QJ; Wang MR
    Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):585-9. PubMed ID: 24314215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
    Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
    Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell HE staining smears and paired cell paraffin sections in detection of epithelial growth factor receptor gene of pleural fluid specimens.
    Hou F; Qi C; Lu Y; Li F; Hao Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 47(1):35-44. PubMed ID: 35545361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition.
    Rotella V; Fornaro L; Vasile E; Tibaldi C; Boldrini L; Chella A; D'Incecco A; Cirigliano G; Chioni A; Lupi C; Sensi E; Ginocchi L; Giovannelli S; Pennucci MC; Fontanini G; Baldini E
    J Exp Clin Cancer Res; 2014 Oct; 33(1):77. PubMed ID: 25300933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
    Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
    APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
    Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
    Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
    Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
    Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
    Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
    J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of PCR methods to evaluate EGFR, KRAS and BRAF mutations in a small number of tumor cells in cytological material from lung cancer patients.
    Lewandowska MA; Jóźwicki W; Jochymski C; Kowalewski J
    Oncol Rep; 2013 Sep; 30(3):1045-52. PubMed ID: 23817662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
    Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A
    Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
    Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
    J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.